[go: up one dir, main page]

WO2002034920A3 - Regulation of human ceruloplasmin-like protein - Google Patents

Regulation of human ceruloplasmin-like protein Download PDF

Info

Publication number
WO2002034920A3
WO2002034920A3 PCT/EP2001/012158 EP0112158W WO0234920A3 WO 2002034920 A3 WO2002034920 A3 WO 2002034920A3 EP 0112158 W EP0112158 W EP 0112158W WO 0234920 A3 WO0234920 A3 WO 0234920A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
regulation
ceruloplasmin
human ceruloplasmin
reagents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/012158
Other languages
French (fr)
Other versions
WO2002034920A2 (en
Inventor
Zhimin Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to AU2002219046A priority Critical patent/AU2002219046A1/en
Publication of WO2002034920A2 publication Critical patent/WO2002034920A2/en
Publication of WO2002034920A3 publication Critical patent/WO2002034920A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0091—Oxidoreductases (1.) oxidizing metal ions (1.16)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90283—Oxidoreductases (1.) acting on superoxide radicals as acceptor (1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reagents which regulate human ceruloplasmin-like protein activity and reagents which bind to human ceruloplasmin-like protein gene products can be used to regulate ceruloplasmin activity. Such regulation is particularly useful for treating cardiovascular disorders, liver disorders, such as Wilson's disease, and CNS disorders, such as Parkinson's disease.
PCT/EP2001/012158 2000-10-24 2001-10-22 Regulation of human ceruloplasmin-like protein Ceased WO2002034920A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002219046A AU2002219046A1 (en) 2000-10-24 2001-10-22 Regulation of human ceruloplasmin-like protein

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24242600P 2000-10-24 2000-10-24
US60/242,426 2000-10-24
US31379601P 2001-08-22 2001-08-22
US60/313,796 2001-08-22

Publications (2)

Publication Number Publication Date
WO2002034920A2 WO2002034920A2 (en) 2002-05-02
WO2002034920A3 true WO2002034920A3 (en) 2002-11-28

Family

ID=26935082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/012158 Ceased WO2002034920A2 (en) 2000-10-24 2001-10-22 Regulation of human ceruloplasmin-like protein

Country Status (2)

Country Link
AU (1) AU2002219046A1 (en)
WO (1) WO2002034920A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091008A1 (en) * 2011-12-20 2013-06-27 The Mental Health Research Institute Of Victoria Method of treating reduced ceruloplasmin functionality in the central nervous system
KR20240159714A (en) * 2023-04-27 2024-11-06 국립해양생물자원관 Composition for preventing or treating neurological disorders related to copper metabolism comprising improved peptide of multicopper oxidase active domain
CN118715208A (en) * 2023-10-20 2024-09-27 广东工业大学 Specific quadridentate copper chelators for the treatment of Wilson's disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025954A2 (en) * 1996-12-09 1998-06-18 Samuel David Gpi-ceruloplasmin, analogs thereof, and methods of use
WO1998039448A2 (en) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
WO2001040466A2 (en) * 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001051636A2 (en) * 2000-01-14 2001-07-19 Incyte Genomics, Inc. Secreted proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025954A2 (en) * 1996-12-09 1998-06-18 Samuel David Gpi-ceruloplasmin, analogs thereof, and methods of use
WO1998039448A2 (en) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
WO2001040466A2 (en) * 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001051636A2 (en) * 2000-01-14 2001-07-19 Incyte Genomics, Inc. Secreted proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 23 November 1999 (1999-11-23), XP002210153, retrieved from EBI Database accession no. AL030998 *
ISHIKAWA K-I ET AL: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES. X. THE COMPLETE SEQUENCES OF 100 NEW CDNA CLONES FROM BRAIN WHICH CAN CODE FOR LARGE PROTEINS IN VITRO", DNA RESEARCH, UNIVERSAL ACADEMY PRESS, JP, vol. 5, no. 3, 30 June 1998 (1998-06-30), pages 169 - 176, XP000980105, ISSN: 1340-2838 *
VULPE CD ET AL.: "Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse", NATURE GENETICS, vol. 21, 1999, pages 195 - 199, XP002210151 *

Also Published As

Publication number Publication date
AU2002219046A1 (en) 2002-05-06
WO2002034920A2 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
WO2002004610A3 (en) Regulation of human dipeptidyl-peptidase iv-like enzyme
WO2002008392A3 (en) Regulation of human matriptase-like serine protease
WO2002034920A3 (en) Regulation of human ceruloplasmin-like protein
WO2002020731A3 (en) Regulation of human protein disulfide isomerase-like enzyme
WO2002072824A3 (en) Human transient receptor potential channel protein.
WO2001068839A3 (en) Regulation of human lipoxin a4 receptor-like protein
WO2001077149A3 (en) Regulation of human cyslt2-like gpcr protein
WO2002062974A3 (en) Regulation of human elongase hselo1-like protein
WO2002022631A3 (en) Regulation of human pyroglutamyl peptidase-like enzyme
WO2002057461A3 (en) Regulation of human adam-ts-like zinc metalloprotease
WO2002081705A3 (en) Regulation of human gnat acetyltransferase-like protein
WO2001068840A3 (en) REGULATION OF HUMAN DIAZEPAM BINDING INHIBITOR/ACYL-CoA-LIKE PROTEIN
WO2002055694A3 (en) Discriminative nucleic acid analysis using clone sequence signatures
WO2002046403A3 (en) Regulation of human patched-like protein
WO2003035862A3 (en) Regulation of human arginase signature-containing protein
WO2002036613A3 (en) Regulation of human patched-like protein
WO2003025174A3 (en) Regulation of human mrp1-like protein
WO2002026999A3 (en) Regulation of human adam-ts-like protein
WO2003023034A3 (en) Regulation of human tau-tubulin kinase
WO2002018566A3 (en) Regulation of human l-asparaginase-like enzyme
WO2002022791A3 (en) Regulation of human pyridoxine 5'-phosphate oxidase
WO2002012460A3 (en) Isolation of a human amine oxidase-like protein
WO2003033709A3 (en) Regulation of human serine/threonine protein kinase
WO2002044351A3 (en) Regulation of human fatty acid coa ligase
WO2002055556A3 (en) Regulation of human voltage gated potassium channel protein kv2.2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP